Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Paul Barnard

Pulmonary Disease Gilbert, AZ Medical Doctor

NPI 1992706717 CMS profile 226402

3303 E Baseline Rd, #208, Gilbert, AZ 85234

Open in the dashboard

General payments

$8,449

495 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Paul Barnard of Gilbert, AZ is reported in the CMS Open Payments database as having received $8,449 across 495 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $816 37
2022 General $2,671 143
2021 General $1,942 111
2020 General $723 46
2019 General $2,296 158

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Barnard
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Paul Barnard were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Paul Barnard Pulmonary Disease median Middle half National median
2019 $2,296 $377 $109–$1,340 $163
2020 $723 $230 $56–$907 $114
2021 $1,942 $269 $68–$1,072 $132
2022 $2,671 $390 $100–$1,457 $149
2023 $816 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. GlaxoSmithKline, LLC. $1,162 96 payments
  2. AstraZeneca Pharmaceuticals LP $1,072 51 payments
  3. Regeneron Healthcare Solutions, Inc. $796 50 payments
  4. Mylan Specialty L.P. $505 34 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $491 23 payments
  6. Jazz Pharmaceuticals Inc. $480 23 payments
  7. Amgen Inc. $473 23 payments
  8. Grifols USA, LLC $441 22 payments
  9. Genzyme Corporation $405 20 payments
  10. Harmony Biosciences LLC $268 12 payments
  11. Other $2,355 141 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $8,420 493 payments
  2. Consulting Fee $16 1 payment
  3. Education $13 1 payment
Products named General payments · program years 2019–2023
  1. DUPIXENT Inflammation And Immunology $796 50 payments
  2. TRELEGY ELLIPTA $691 64 payments
  3. SPIRIVA RESPIMAT $470 24 payments
  4. DUPIXENT Immunology $465 23 payments
  5. TEZSPIRE $421 21 payments
  6. Prolastin-C Liquid $400 20 payments
  7. BREZTRI $371 13 payments
  8. FASENRA $359 12 payments
  9. YUPELRI $298 19 payments
  10. NUCALA $293 18 payments
  11. Other $5,122 284 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

495 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record